Opinion: On “Funding Research in Africa”

A letter to The Scientist from NIH Director Francis Collins and Wellcome Trust Director Jeremy Farrar

Written byFrancis S. Collins and Jeremy Farrar
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, NICOLAS RAYMONDWe are writing to comment on your November 12 article entitled “Funding Research in Africa” by Paula Park. The article appropriately identified a very real problem—the dearth of basic research funding for scientists in many African countries. While the US National Institutes of Health (NIH), the Wellcome Trust, and others fund a considerable amount of research in Africa, many of those awards are made to non-African institutions and scientists, who in turn sub-contract for collaborations with their African colleagues. However, Park apparently did not appreciate that the proportion of awards made directly to African scientists and institutions is steadily increasing, and now accounts for about 40 percent of Wellcome Trust and 63 percent of NIH funding for research in Africa.

As a prominent example of this increasing focus on direct funding to African investigators, the NIH and the Wellcome Trust recently established a collaborative program, called Human Health and Heredity in Africa (H3Africa). H3Africa directly funds African scientists at African institutions to conduct research on the genomic and environmental bases of health problems of importance in Africa. Support is being provided for basic research, improved infrastructure, and training. One of the long-term goals of H3Africa is to increase the ability of African scientists to compete for international research funding.

NIH and the Wellcome Trust have, together, committed the equivalent of at least $76 million to H3Africa for the period 2012–2016, and both agencies will consider extending the program for an additional five years pending the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies